

Cost of failure to treat autoimmune thyroiditis in thyroid cancer initiation and growth

Stephen J. Merrill

Program in Computational Sciences

Department of MSCS

Marquette University


Milwaukee, Wisconsin USA

Thyroid Gland

- One of the largest endocrine gland, controlling metabolism in the body
- Also controls how the body should react to other hormones (such as products of the adrenal gland)
- Produces two hormones, T3, which has 3 atoms of iodine and T4, which has 4.
- T3 is the active form, produced from T4 by one of two deiodination enzymes.
- Hypothyroidism (low T4) is most commonly caused by an autoimmune condition. Incidence is increasing world-wide
- Hypothyroidism is usually treated by hormone replacement with synthetic T4, Levothyroxine.

Basic Idea

- Basic feedback control -- the HPT axis.
- This control is disrupted in autoimmune (Hashimoto's) thyroiditis
- As the thyroid is slowly destroyed, the thyroid is unable to respond to the TSH signal
- As T4 falls -- TSH increases.



Consequences of increasing TSH

- Areas of the thyroid are stimulated to grow, forming “nodules” of follicular cells (the T4-producing cells).
- The overall size of the thyroid can grow dramatically, forming a temporary thyroid goiter.
- In the face of autoimmune thyroiditis, there is a large inflammatory response and sometimes a large short-term release of T4, Hashitoxicosis.
- For any cancers that form in a nodule, TSH acts as a hormonal growth factor.

Thyroid Nodules

- Found in 20-70% of the population
- About 5% (and to up to 15% in thyroiditis) are malignant
- Main type of thyroid cancer is carcinoma, papillary (75%), follicular (10%), other types (15%).
- Treatment options: thyroidectomy sometimes followed by radioactive iodine or TSH suppression by levothyroxin (T4)


Outline of the model

- 1. Due to the nature of the process, a stochastic model (with a continuous input) is chosen.**
- 2. In any Δt of time, a region in the thyroid may be stimulated to begin a nodule. This rate is determined by TSH.**
- 3. Growth of an existing nodule is determined by TSH.**
- 4. Cancer development rate is determined by the nodule growth rate. Once started, growth rate of a cancerous nodule is greater than the growth rate of other nodules.**

How many areas get a nodule initiation signal?


- Assuming N potential growth sites, consider the distribution of M TSH molecules distributed to the N sites (assuming a large signal would mean a nodule initiation).
- Number of molecules per site follows a binomial distribution. Counting the number of sites that exceed a threshold given M molecules in this case can be approximated by $\frac{TSH^4}{K + TSH^4}$ for some K .

Number of Nodules



Over 30 years, effect of elevated TSH.

Largest Nodule increases with TSH



**Frequency of large, 4 cm nodules increases if TSH increases.
Half of these may be cancerous in autoimmune thyroiditis.**

The connection to autoimmune thyroiditis

- There can be a long period of asymptomatic hypothyroidism (T4 normal or low, TSH increasing).
- Treatment (with levothyroxin) is often started when TSH is beyond normal reference (4-5 $\mu\text{U/mL}$).
- This can result in a long (several year) period where TSH is high and nodule formation is encouraged.
- In undiagnosed conditions, TSH can reach very high levels, raising the risk of cancer.

Question of Interest

- **What is the cost (in terms of increased thyroid cancer) for late treatment of hypothyroidism?**
 - **Approach is to compare the untreated and treated simulated populations and to compare cancer incidence.**
 - **Need to find a way to mimic the natural changes in TSH in this disease.**

Model of Autoimmune Thyroiditis

- The work of a doctoral student, Bala Pandiyan, along with Dr. Salvatore Benvenga, University of Messina in Sicily and an undergraduate McNair Fellow, Mike Castillo (Marian University)
- Based on data from Benvenga's clinic of hundreds of thyroiditis patients.
- Describes the disruption of the feedback system's ability to keep TSH and T4 at set levels as a result of the disease.
- Takes the form of a nonlinear system of differential equations.

Pandiyan's Model

- **T is the functional (active) size of the thyroid**

$$\frac{d(TSH)}{dt} = k_1 - \frac{k_1 T 4}{k_a + T 4} - k_2 TSH$$


$$\frac{d(T 4)}{dt} = \frac{k_3 T (TSH)}{k_d + TSH} - k_4 T 4$$
- **Ab is the level of antithyroid antibodies (TPOAb) and TgAb**

$$\frac{dT}{dt} = k_5 \left(\frac{TSH}{T} - N \right) - k_6 (Ab) T$$


$$\frac{d(Ab)}{dt} = k_7 (Ab) T - k_8 Ab$$

Parameters

- Determined by the literature, data, equilibrium arguments, and simulation.
- Typical drop in T4 which results in a corresponding large increase in TSH. $\log(\text{TSH})$ is nearly linear in T4.




TSH increases over time




Behavior of the model

- Depends on parameter k_7 . If that parameter is small, the normal “euthyroid” state is globally stable, attracting all solutions (that is, the system maintains itself). If that parameter is large, there is a new stable equilibrium and the system works its way toward that new equilibrium over a period of years.

Disease Progression




Untreated




With Treatment

TSH returns
To normal
levels



Nodule sizes – with Treatment



Summary

- **A dynamic model of autoimmune thyroiditis enables one to study consequences of the disease, such as initiation and growth of thyroid cancer.**
- **Similar studies could be done to study other treatment effects, such as side effects or even patient satisfaction.**
- **Patient-specific parameters can be identified.**

Thank You!



Much of this presented work was joint with Mike Castillo (no picture available)